TABLE 5.
Brain and plasma concentrations of L-DOPA and VU0364770 after systemic administration of VU0364770 (100 mg/kg s.c.) alone or in combination with l-DOPA (1.5 mg/kg i.p.) and benserazide (15 mg/kg i.p.)
Data are means ± S.E.M. of five to seven animals; no significant treatment effects (P > 0.23, t-test).
| Pretreatment (t = 0 min) | Treatment (t = 60 min) | L-DOPA (t = 120 min) |
VU0364770 (t = 120 min) |
||
|---|---|---|---|---|---|
| Plasma | Brain | Plasma | Brain | ||
| ng/ml | ng/g | ng/ml | ng/g | ||
| Vehicle | Vehicle | N.D. | N.D. | ||
| Vehicle | l-DOPA/benserazide | 2350 ± 49 | 433 ± 46 | ||
| VU0364770 | Vehicle | N.D. | N.D. | 316 ± 34 | 1476 ± 14 |
| VU0364770 | l-DOPA/benserazide | 2330 ± 12 | 403 ± 17 | 308 ± 47 | 1823 ± 24 |
N.D., not detected.